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Enantioselective Total Synthesis of (–)-Myrifabral A and B 
Tyler J. Fulton,[a] Anthony Y. Chen,[a] Michael D. Bartberger,[b] and Brian M. Stoltz*,[a] 
A catalytic enantioselective approach to the myrioneuron alkaloids (–)-myrifabral A and (–)-myrifabral B is described.  The synthesis was enabled by a 
palladium-catalyzed enantioselective allylic alkylation, that generates the C(10) all-carbon quaternary center.  A key N-acyl iminium ion cyclization forged the 
cyclohexane fused tricyclic core, while vinyl boronate cross metathesis and oxidation afforded the lactol ring of (–)-myrifabral A.  Adaptation of previously 
reported conditions allowed for the conversion of (–)-myrifabral A to (–)-myrifabral B. 
 
Introduction 
 The Myrioneuron alkaloids are a small, yet growing family of 
structurally diverse polycyclic (tri-, tetra-, penta-, hexa-, and 
decacyclic) alkaloids believed to share a common biosynthetic 
origin from lysine (Figure 1).1  The first Myrioneuron alkaloids 
from Myrioneuron nutans were reported in 2002, with 
altogether 10 structures reported to date.2  Since 2013, many 
new alkaloids have been isolated from Myrioneuron faberi,3 
Myrioneuron tonkinesis,4 and Myrioneuron effusum.5  In 
addition to their interesting structural features, a number of of 
these alkaloids possess a range of biological activities such as 
antimalarial properties, KB cell cytotoxicity, antimicrobial, and 
hepatitis C virus (HCV) replication inhibition.1–5  Despite 
possessing promising biological properties and synthetically 
attractive motifs, relatively few of these alkaloids have been 
prepared by total synthesis efforts.2d,e,6   
 
 
 
Figure 1. Representative myrioneuron alkaloids. 
 
 
 We became interested in (±)-myrifabral A (4) and (±)-
myrifabral B (5) in particular due to their unique cyclohexane 
fused octahydroquinolizine skeletons which contain four 
contiguous stereogenic centers, including an all-carbon 
quaternary center embedded in the cyclohexane fusion.  
Interestingly, both 4 and 5 are isolated as racemic mixtures of 
a- and b-hydroxy epimers.  Even as racemates, these clusters 
display promising HCV replication inhibition (EC50 = 4.7 for (±)-
a,b-OH-4 and 2.2 µM (±)-a,b-OH-5, respectively) with 
significantly reduced liver cell cytotoxicity compared to 
commercial pharmaceutical HCV drug telaprevir (EC50 = 0.09 
µM).3c  She et al recently reported a rapid total synthesis of (±)-
a,b-OH-4 and (±)-a,b-OH-5, however, no asymmetric  
 
approaches have been disclosed to date.6c  To enable further 
studies of these alkaloids in each enantiomeric series, we report  
herein a short, catalytic enantioselective synthesis (–)-a,b-OH-
4 and (–)-a,b-OH-5. 
In devising our strategy, we targeted (–)-myrifabral A (4), which 
can be directly converted to (–)-myrifabral B (5), as reported by She 
(Scheme 1).6c  Retrosynthetically, we envisioned (–)-myrifabral A (4) 
could be simplified to tricyclic lactam (6).  Importantly, the versatile 
ketone, allyl, and lactam functional handles in tricyclic lactam 6 
provide ample opportunity for future diversification of the natural 
product scaffold for medicinal chemistry efforts and potential 
derivative synthesis.  We envisioned the critical C(6)–C(7) bond could 
arise by means of a diastereoselective N-acyl iminium ion cyclization 
of enantioenriched ketone 7.7  Finally, the C(10) all-carbon 
quaternary center could be forged in an enantioselective manner by 
means of asymmetric allylic alkylation of glutarimide 8.  In turn, 
glutarimide 8 could be prepared from b-ketoester 9. 
 
Scheme 1. Retrosynthetic analysis of (–)-myrifabral A. 
Results and discussion 
Our synthetic efforts commenced with the preparation of 
glutarimide 8 (Scheme 2).  Alkylation of b-ketoester 9 with 
sulfonylmethyl carbamate 10 in the presence of Cs2CO3 proceeded 
smoothly on a 30.0 g scale to afford a-aminoketone 11 in 95% yield.8  
Elaboration of the Boc-protected amine to glutarimide 8 with 
standard protocols was low yielding and required three separate 
reactions.  This inspired us to develop a more practical, one-pot 
procedure to enable the installation of the glutarimide moiety (Table 
1).  Initially, trifluoroacetic acid mediated conditions were explored, 
with the most promising results observed in 3:1 DMF/TFA at refluxing 
temperature (entry 1) and 3:1 1,4-dioxane/TFA (entry 2).  Further 
investigation revealed that stoichiometric boric acid could mediate 
N
O
OH
N
O
OH
(±)-α-Myrifabral A (4) (±)-α-Myrifabral B (5)
NEt2
N
N
O
H
HH
H
(+)-Myriberine (1)
N
O
H
H H
(+)-Myrioxazine A (2)
H N O
OH
(+)-Myrioneurinol (3)
6
N
7
O
O
N
O
OO O
N
O
O
N-Acyl Iminium
Ion Cyclization
Enantioselective
Allylic Alkylation
10
O
N
O
O
O
O
6 7
8
N
O
OH
NEt2 ref 6c N
O
OH
Reduction/Olefin 
Oxidation
(–)-α-Myrifabral A (4)(–)-α-Myrifabral B (5)
O
O
O
9
7
  
the transformation in excellent yield in xylenes at 140 °C (entry 
3).  While aryl boronic acids9 and boric acid10 have been 
demonstrated as effective catalysts for amidation of carboxylic acids 
with amines, we were surprised to observe commensurate Boc 
removal, amidation, and glutarimide cyclization.  Control 
experiments revealed the reaction only proceeds with the complete 
set of reagents (entries 4–6).  Furthermore, Boc protected a-
aminoketone 11 was stable to xylenes at reflux for 120 h (entry 7).  
Additional examination revealed catalytic boric acid (10 mol %) with 
2 equivalents of glutaric anhydride (12) performed equally well as 
our best conditions (entry 8).  Replacing glutaric anhydride (12) with 
glutaric acid (13) as a cheaper alternative did not affect the reaction 
time or yield (entry 9) Pleasingly, the reaction time could be reduced 
by utilizing catalytic PhB(OH)2 as a soluble boronic acid (entry 10), 
although this benefit was tempered on larger scales (entry 11).  
Optimal results were obtained by utilizing the electron deficient 
catalyst 4-CF3PhB(OH)2 (entry 12).   
 
Scheme 2. Initial synthesis of glutarimide 8. 
These optimized conditions for elaboration of Boc protected a-
aminoketone 11 to glutarimide 8 performed well on a 15.0 g scale, 
enabling us to press forward in our synthetic campaign (Scheme 3).  
Palladium-catalyzed decarboxylative asymmetric allylic alkylation of 
glutarimide 8 established the C(10) all-carbon quaternary center, 
affording ketone 7 in 94% yield and 88% ee.  The absolute 
configuration of the all-carbon quaternary was established as (S) via 
experimental and computational vibrational circular dichroism (VCD) 
and optical rotation analyses.11  To affect the key N-acyl iminium ion 
cyclization, the ketone was first protected as ethyl vinyl ether 14.  A 
one-pot protocol was then employed to affect mono-reduction of 
the glutarimide with LiEt3BH followed by BF3•OEt2 mediated N-acyl 
iminium ion cyclization of intermediate N-acyl hemiaminal 15, 
furnishing tricyclic lactam 6 as a single diasteromer in 81% yield over 
three steps.   
Table 1. Development of a one-pot conversion of Mannich adduct 11 to glutarimide 8. 
entry Conditions[a] % yield[b] 
1 3:1 DMF/TFA (0.10 M), 12 (4 equiv), reflux, 48 h 60 
2 3:1 1,4-dioxane/TFA (0.10 M), 12 (4 equiv), reflux, 48 h 70 
3 B(OH)3 (3.0 equiv), 12 (4 equiv), xylenes, Dean–Stark, reflux, 36 h 90–95 
4 B(OH)3 (3.0 equiv) xylenes, Dean–Stark, reflux, 72 h >95% 11  
5 12 (4 equiv), xylenes, Dean–Stark, reflux, 72 h >95% 11 
6 13 (4 equiv), xylenes, Dean–Stark, reflux, 72 h >95% 11 
7 xylenes, Dean–Stark, reflux, 120 h >95% 11 
8 B(OH)3 (10 mol %), 12 (2 equiv), xylenes, Dean–Stark, reflux, 36 h 90–95 
9 B(OH)3 (10 mol %), 13 (2 equiv), xylenes, Dean–Stark, reflux, 36 h 90–95 
10 PhB(OH)2 (10 mol %), 13 (2 equiv), xylenes, Dean–Stark, reflux, 24 h 90–95 
11 PhB(OH)2 (10 mol %), 13 (2 equiv), xylenes, Dean–Stark, reflux, 36 hc 90–95 
12 4-CF3PhB(OH)2 (10 mol %), 13 (2 equiv), xylenes, Dean–Stark, reflux, 24 hc 90–95 
a Reaction performed on a 0.16 mmol scale unless otherwise stated, b Isolated 
yield, c Reaction performed on a 0.80 mmol scale.
 
Scheme 3. Enantioselective synthesis of tricyclic lactam 6.
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Completion of the synthesis required reduction of the lactam and 
ketone and elaboration of the terminal olefin to an aldehyde (Scheme 
4).  Toward that end, a one-pot procedure was developed wherein the 
ketone was first reduced by L-Selectride with exceptional 
diastereoselection (>19:1).  Following the reduction of the ketone, 
addition of LiAlH4 and heating to reflux afforded full reduction of the 
lactam to the corresponding tertiary amine.  A modified Fieser work 
up then provided desired amino alcohol 16 in 97% yield.  Initially, we 
found the terminal olefin recalcitrant to both direct and two-step 
oxidations to the aldehyde due to challenges with olefin isomerization 
and undesired or poor reactivity.  To our delight, olefin cross 
metathesis using Hoveyda–Grubbs II catalyst of amino alcohol 16 
with vinyl boronic acid pinacol ester (17) as an aldehyde surrogate 
smoothly afforded metathesis product 18.  Elaboration of the vinyl 
boronate was then affected by deprotection and oxidation of the 
boronic acid, with in situ lactolization providing (–)-myrifabral A in 
50% yield.  X-ray crystallography allowed for the determination of 
the absolute stereochemistry of the (–)-myrifabral A enantiomeric 
series.  Adaptation of She’s conditions for the synthesis of (±)-
myrifabral B then provided access to (–)-myrifabral B in 70% yield 
(Scheme 5).6c Interestingly, both (–)-myrifabral B, and (–)-myrifabral 
A are isolated as oils, whereas racemates of these compounds are 
isolated as solids.3c,6c  Spectroscopic data obtained were in excellent 
agreement with the natural compound (see Supporting Information). 
 
 
Scheme 4. End game for (–)-myrifabral A. 
Scheme 5. Synthesis of (–)-myrifabral B. 
Conclusions 
     We have described the first enantioselective total synthesis of 
(–)-myrifabral A and B.  Critical to the success of this strategy 
was the development of a direct and high yielding one-pot 
conversion of a Boc-protected amine (11) to the glutarimide (8).  
Palladium catalyzed decarboxylative asymmetric allylic 
alkylation provided the C(10) all-carbon quaternary center in 
88% ee, setting the stage for ketone protection, glutarimide 
reduction, and an exquisitely diastereoselective N-acyl iminium  
 
ion cyclization.  Following ketone and lactam reduction, cross 
metathesis with vinyl boronic acid pinacol boronate and 
subsequent boronic acid deprotection and oxidation afforded (–
)-myrifabral A.  Utilizing previously reported conditions, (–)-
myrifabral A was converted to (–)-myrifabral B.  This marks the 
first catalyst-controlled asymmetric synthesis of myrifabral A 
and B, enabling future biological study of individual 
enantiomeric series. 
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Materials and Methods  
Unless otherwise stated, reactions were performed in flame-dried glassware under an argon or 
nitrogen atmosphere using dry, deoxygenated solvents.  Solvents were dried by passage through 
an activated alumina column under argon.1 Reaction progress was monitored by thin-layer 
chromatography (TLC) or Agilent 1290 UHPLC-MS.  TLC was performed using E. Merck silica 
gel 60 F254 precoated glass plates (0.25 mm) and visualized by UV fluorescence quenching, p-
anisaldehyde, oxr KMnO4 staining.  Silicycle SiliaFlash® P60 Academic Silica gel (particle size 
40–63 µm) was used for flash chromatography.  1H NMR spectra were recorded on Varian Inova 
500 MHz and Oxford 600 MHz spectrometers and are reported relative to residual CHCl3 (δ = 7.26 
ppm) or TMS (δ = 0.00 ppm).  13C NMR spectra were recorded on a Bruker 400 MHz spectrometer 
(100 MHz) and are reported relative to CHCl3 (δ = 77.16 ppm), C6D6 (δ = 128.06 ppm) . Data for 
1H NMR are reported as follows: chemical shift (δ ppm) (multiplicity, coupling constant (Hz), 
integration).  Multiplicities are reported as follows: s = singlet, d = doublet, t = triplet, q = quartet, 
p = pentet, sept = septuplet, m = multiplet, br s = broad singlet, br d = broad doublet.  Data for 13C 
NMR are reported in terms of chemical shifts (δ ppm).  IR spectra were obtained by use of a Perkin 
Elmer Spectrum BXII spectrometer or Nicolet 6700 FTIR spectrometer using thin films deposited 
on NaCl plates and reported in frequency of absorption (cm–1).  Optical rotations were measured 
with a Jasco P-2000 polarimeter operating on the sodium D-line (589 nm), using a 100 mm path-
length cell.  High resolution mass spectra (HRMS) were obtained from Agilent 6200 Series TOF 
with an Agilent G1978A Multimode source in electrospray ionization (ESI+), atmospheric 
pressure chemical ionization (APCI+), or mixed ionization mode (MM: ESI-APCI+). Reagents 
were purchased from commercial sources and used as received unless otherwise stated.  
List of Abbreviations: 
TLC – thin-layer chromatography 
VCD – vibrational circular dichroism 
PHOX – phosphinooxazoline 
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a-aminomethyl β-keto ester (11) 
Compound 11 was prepared as previously described by Stoltz et al.2  To a stirred solution of β-
keto ester 9 (20.0 g, 120.3 mmol, 1.0 equiv) in CH2Cl2 (600 mL) was added sulfonylmethyl 
carbamate 10 (39.2 g, 144.4  mmol, 1.2 equiv) in one portion at ambient temperature. After stirring 
for 5 min, Cs2CO3 (98.0 g, 300 mmol, 2.5 equiv) was added in one portion.  The resulting white 
suspension was stirred vigorously at 20 ºC.  After 16 h, full consumption of starting material was 
determined by TLC analysis.  Saturated aqueous ammonium chloride (300 mL) was added slowly, 
and the biphasic mixture was stirred at ambient temperature for 40 min and extracted with CH2Cl2 
(3 x 100 mL).  The combined organic layers were dried over Na2SO4, filtered, and concentrated to 
a viscous, colorless oil. Flash column chromatography (SiO2, 10% EtOAc in hexanes) afforded α-
aminomethyl β-keto ester 11 as an amorphous white solid (35.61 g, 114.36 mmol, 95% yield); 1H 
NMR (500 MHz, CDCl3) δ 5.91 (ddt, J = 17.2, 10.4, 5.9, 1H), 5.33 (dq, J = 17.2, 1.4, 1H), 5.25 
(dd, J = 10.4, 1.4 Hz, 1H), 5.17 (t, J = 5.7 Hz, 1H), 4.63 (d, J = 5.8 Hz, 1H), 3.55 (dd, J = 13.9, 
7.7 Hz, 1H), 3.41 (dd, J = 13.9, 5.7 Hz, 1H), 2.63–2.34 (m, 3H), 2.07–1.94 (m, 1H), 1.87–1.75 (m, 
1H), 1.74 – 1.53 (m, 4H), 1.41 (s, 9 H);13C NMR (100 MHz, CDCl3) δ 208.9, 170.9, 155.9, 131.6, 
119.2, 79.4, 66.3, 62.4, 44.3, 40.8, 33.8, 28.4, 27.2, 22.1; IR (Neat Film, NaCl) 3460, 2936, 2869, 
1712, 1501, 1451, 1391, 1366, 1315, 1225, 1202, 1170, 1140, 1099, 931, 856 cm–1; HRMS 
(MM:ESI-APCI+) m/z calc’d for C16H26NO5 [M+H]+: 312.1805, found 312.1805. 
 
Glutarimide 8   
A flame-dried 2 L round bottom flask equipped with a Dean–Stark trap, a reflux condenser 
and a stirring bar was charged with 11 (15.00 g, 48.17 mmol, 1.0 equiv), glutaric acid (12.73 g, 
96.35 mmol, 2.0 equiv), 4-CF3PhB(OH)2 (915.3 mg, 4.82 mmol, 10 mol %), and xylenes (960 
mL).  The resulting suspension was heated to reflux in a heating mantle with vigorous stirring.  
O
O
O
Cs2CO3 (2.5 equiv)
CH2Cl2, 23 ºC, 16 h
9
O
BocHN
O
O
11
PhO2S NHBoc (10)
(1.2 equiv)
O
N
O
O
O
O
O
BocHN
O
O 4-CF3PhB(OH)2 (10 mol %)
glutaric acid (2.0 equiv)
xylenes, reflux
Dean–Stark, 48 h
11 8
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After 48 h, the light orange reaction solution was cooled to 20 ºC and concentrated to provide a 
crude orange oil.  The crude oil was purified by column chromatography (2 → 5% EtOAc in 
CH2Cl2) to afford an off white semisolid which was further purified by column chromatography 
(SiO2, 20→ 40% EtOAc in hexanes) to provide 8 as an amorphous white solid (12.62 g, 41.05 
mmol, 85% yield); 1H NMR (500 MHz, CDCl3) δ 5.94 (dddd, J = 17.3, 10.4, 6.1, 5.6 Hz, 1H), 
5.33 (dd, J = 17.3, 1.5 Hz, 1H), 5.25 (dd, J = 10.4, 1.5 Hz, 1H), 4.66 (ddt, J = 13.1, 6.1, 1.2 Hz, 
1H), 4.53 (ddt, J = 13.1, 5.6, 1.2 Hz, 1H), 4.32 (ABq, ΔδAB = 0.05, JAB = 14.1 Hz, 2H), 2.64 (t, J 
= 6.5 Hz, 4H), 2.48–2.36 (m, 2H), 2.30–2.24 (m, 1H), 2.03–1.97 (m, 1H), 1.94 (p, J = 6.6 Hz, 2H), 
1.77–1.70 (m, 1H), 1.67–1.49 (m, 3H); 13C NMR (100 MHz, CDCl3) δ 206.0, 172.8, 169.8, 131.5, 
118.6, 66.4, 59.6, 41.9, 40.9, 34.0, 32.8, 27.1, 22.2, 16.7; IR (Neat Film, NaCl) 2942, 1711, 1681, 
1426, 1379, 1334, 1265, 1204, 1122, 1098, 1057, 1020 cm–1; HRMS (MM:ESI-APCI+) m/z calc’d 
for C16H22NO5 [M+H]+: 308.1492, found 308.1504. 
 
 
Ketone 7  
 An oven-dried 1 L round bottom flask was charged with Pd2(dba)3 (819.6 mg, 0.895 mmol, 
2.75 mol %), (S)-(CF3)3-t-BuPHOX (1.1548 g, 1.95 mmol, 6.0 mol %), and a magnetic stirring bar 
in a N2-filled glovebox. The flask was then charged with toluene (650 mL) and stirred at 24 ºC for 
40 min, generating a dark orange/red solution.  The preformed catalyst solution was then 
cannulated into a solution of 8 (10.0 g, 32.54 mmol, 1.0 equiv) dissolved in toluene (325 mL) in a 
2 L flame-dried round bottom flask.  The resulting dark green solution was stirred at 24 ºC.  Full 
consumption of the starting material was achieved after 7 h, as determined by TLC analysis (25% 
EtOAc in hexanes).  The crude reaction mixture was concentrated and directly purified by column 
chromatography (SiO2, 10 → 40% EtOAc in hexanes) to yield glutarimide 7 as an off white semi-
solid (8.06 g, 30.6 mmol, 94% yield); 88% ee, [α]D25 +32.9 (c 1.0, CHCl3); 1H NMR (500 MHz, 
C6D6) δ 5.67 (dddd, J = 16.7, 10.3, 8.4, 5.9 Hz, 1H), 5.04–4.94 (m, 2H), 4.12 (ABq, ΔδAB = 0.22, 
Pd2(dba)3 (2.5 mol %)
(S)-(CF3)3-t-BuPHOX (6 mol %)
toluene, 23 ºC, 7 h
O
N
O
O
8
O
O
N
O
O
7
O
P
CF3
F3C
CF3
(S)-(CF3)3-t-BuPHOX
N
O
t-Bu
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JAB = 13.7 Hz, 2H), 2.90 (ddd, J = 15.6, 12.4, 6.2 Hz, 1H), 2.63 (t, J = 6.4 Hz, 4H), 2.38 (ddt, J = 
14.2, 5.8, 1.3 Hz, 1H), 2.32 (dt, J = 15.8, 4.4 Hz, 1H), 2.01–1.87 (m, 4H), 1.83–1.68 (m, 4H), 
1.64–1.53 (m, 1H); 13C NMR (100 MHz, CDCl3) δ 213.2, 173.2, 134.7, 118.2, 51.8, 44.2, 39.6, 
38.7, 35.3, 33.1, 26.1, 21.2, 16.8; IR (Neat Film, NaCl) 3072, 2937, 2864, 1727, 1701, 1679, 1638, 
1430, 1380, 1340, 1319, 1243, 1173, 1120, 1056, 1008, 914, 868, 803 cm–1; HRMS (MM:ESI-
APCI+) m/z calc’d for C15H22NO3 [M+H]+: 264.1594, found 264.1591; SFC Conditions: 35% IPA, 
3.5 mL/min, Chiralpak AD-H column, λ = 210 nm, tR (min): major = 1.28, minor = 1.68.  
 
 
 
Determination of Absolute Configuration of 7 and ent-7. 
 
Method 1 – Vibrational Circular Dichroism (VCD) 
Experimental Protocol.  Solutions of compounds 7 and ent-7 (69 mg/mL) were each prepared in 
CDCl3 and loaded into a front-loading SL-4 cell (International Crystal Laboratories) possessing 
BaF2 windows and 100 μm path length.   Infrared (IR) and VCD spectra were individually acquired 
on a BioTools ChiralIR-2X VCD spectrometer as sets of 24 one-hour blocks (24 blocks, 3120 
scans per block) at 4 cm–1 resolution in dual PEM mode.  A 15-minute acquisition of neat (–)-α-
pinene control (separate 75 μm BaF2 cell) yielded a VCD spectrum in agreement with literature 
spectra and those previously acquired on the same instrument.  IR and VCD spectra were 
background-corrected using a 30-minute block IR acquisition of the empty instrument chamber 
under gentle N2 purge, and were solvent corrected using a 12-hour (12 blocks, 3120 scans per 
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block) IR/VCD acquisition of CDCl3 in the same 100 μm BaF2 cell as used for 7 and ent-7.  The 
reported spectra represent the result of block averaging. 
Computational Protocol.  The arbitrarily chosen (R) enantiomer of compound 7 was subjected to 
an initial exhaustive stochastic molecular mechanics-based conformational search (MMFF94 force 
field, 0.06 Å geometric RMSD cutoff, and 30 kcal/mol energy window) as implemented in MOE 
2019.0102 (Chemical Computing Group, Montreal, CA).  All conformers retained the (R) 
configuration and were subjected to geometry optimization, harmonic frequency calculation, and 
VCD rotational strength evaluation using density functional theory.  Initial quantum mechanical 
calculations utilized the B3LYP functional, small 6-31G* basis, and IEFPCM model (chloroform 
solvent) as an initial filter.  This was followed by subsequent treatment using the B3PW91 
functional, cc-pVTZ basis, and implicit IEFPCM chloroform solvation model on all IEFPCM-
B3LYP/6-31G* conformers below 5 kcal/mol, reusing the exact Hessian of the latter to facilitate 
optimization at the higher level of theory.   All calculations were performed with the Gaussian 16 
program system (Rev. C.01; Frisch et al., Gaussian, Inc., Wallingford, CT).  Resultant IEFPCM-
B3PW91/cc-pVTZ harmonic frequencies were scaled by 0.98. All structurally unique conformers 
possessing all positive Hessian eigenvalues were Boltzmann weighted by relative free energy at 
298.15 K.  The predicted IR and VCD frequencies and intensities of the retained conformers were 
convolved using Lorentzian line shapes (γ = 4 cm–1) and summed using the respective Boltzmann 
weights to yield the final predicted IR and VCD spectra.  The predicted VCD spectrum of the (S) 
enantiomer was generated by inversion of sign.  From the outstanding agreement between the 
theoretical and measured IR and VCD spectra across the entire useful range of the spectrum (900–
1500 cm–1; regions A–J below) along with support of this assignment using the directly predicted 
versus measured optical rotations (see Method 2) the absolute configurations of species 7 and ent-
7 were established as (S) and (R), respectively. 
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Experimental (left) and computed (right) IR and VCD spectra of 7 and ent-7. 
 
Method 2 – Optical Rotation (OR) 
Computational Protocol.  The ensemble of unique IEFPCM-B3PW91/cc-pVTZ conformers of 
(R)-7 generated in Method 1 above were subjected to optical rotation calculation at 589.0 nm using 
the B3LYP hybrid density functional, the large and diffuse 6-311++G(2df,2pd) basis set, and the 
IEFPCM implicit chloroform solvent model.  The computed IEFPCM-B3LYP/6-
311++G(2df,2pd) optical rotations (weighted by IEFPCM-B3PW91/cc-pVTZ free energies at 
298.15 K) along with those resulting from alternatively weighting by either the IEFPCM-
B3PW91/cc-pVTZ total energies or IEFPCM-B3LYP/6-311++G(2df,2pd)//IEFPCM-
B3PW91/cc-pVTZ total energies are reported in (a)–(b) below.  From comparison of the 
theoretically calculated and measured optical rotations (for which reasonably good agreement in 
magnitude was found to exist) the respective VCD-based AC assignments of (S) and (R) for 7 and 
ent-7 were further supported by those from the separate OR-based methodology.  The individual 
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relative energies, free energies, and optical rotation signatures of each conformer of (R)-7 are 
provided in the accompanying Microsoft Excel file. 
(a)  
Predicted optical rotation, weighted by IEFPCM-B3PW91/cc-pVTZ free energies:  –47.5° 
Predicted optical rotations, weighted by IEFPCM-B3PW91/cc-pVTZ total energies:  –45.5° 
Predicted optical rotations, weighted by IEFPCM-B3LYP/6-311++G(2df,2pd)//IEFPCM-
B3PW91/cc-pVTZ total energies:  –45.8°     ∴ 
(b)  
Predicted optical rotation, weighted by IEFPCM-B3PW91/cc-pVTZ free energies:  +47.5° 
Predicted optical rotations, weighted by IEFPCM-B3PW91/cc-pVTZ total energies:  +45.5° 
Predicted optical rotations, weighted by IEFPCM-B3LYP/6-311++G(2df,2pd)//IEFPCM-
B3PW91/cc-pVTZ total energies:  +45.8°     
 
Measured optical rotation: (CHCl3 solvent, 25 °C, c = 10.0 mg/mL, 10 cm pathlength, 88% ee)  
7: + 32.9 
ent-7: –28.9 
 
 
Ethyl vinyl ether 14  
A flame-dried 250 mL round bottom flask was charged with 7 (3.00 g, 11.4 mmol, 1.0 
equiv), EtOH (114 mL), p-TsOH•H2O (43.4 mg, 0.228 mmol, 0.02 equiv), and CH(OEt)3 (38.0 
(R)
O
N
O
O
(S)
O
N
O
O
CH(OEt)3 (20.0 equiv)
p-TsOH•H2O (2 mol %)
EtOH, 40 ºC, 16 h
O
N
O
O
7
OEt
N
O
O
14
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mL, 228 mmol, 20.0 equiv).  The resulting clear, colorless solution was heated in a 40 ºC heating 
block for 16 h, after which time complete conversion was observed by TLC analysis (40% EtOAc 
in hexanes).  The reaction mixture was concentrated under reduced pressure and the resulting 
colorless oil was dissolved in EtOAc (50 mL) and poured into a separatory funnel containing 
saturated aqueous NaHCO3 (50 mL).  The layers were separated and the aqueous layer was 
extracted with EtOAc (2 x 100 mL). The combined organics were washed with brine (25 mL), 
dried over Na2SO4, filtered, and concentrated. Flash column chromatography (SiO2, 30% EtOAc 
in hexanes) provided 14 as a colorless oil (3.0326 g, 10.41 mmol, 91% yield); [α]D25 –72.6 (c 1.0, 
CHCl3); 1H NMR (500 MHz, C6D6) δ 5.90 (dddd, J = 17.3, 10.0, 9.2, 5.3 Hz, 1H), 5.18–5.01 (m, 
2H), 4.66–4.54 (m, 1H), 4.35 (ABq, ΔδAB = 0.23, JAB = 13.1 Hz, 2H), 3.55–3.31 (m, 2H), 2.95 
(ddt, J = 13.4, 5.1, 1.3 Hz, 1H), 2.14–1.81 (m, 8H), 1.77–1.64 (m, 1H), 1.64–1.50 (m, 2H), 1.10 
(t, J = 7.0 Hz, 3H), 1.06 – 0.91 (m, 2H); 13C NMR (100 MHz, C6D6) δ 172.2, 156.5, 136.4, 117.1, 
96.6, 61.8, 45.1, 42.7, 41.4, 33.2, 31.8, 24.5, 19.5, 16.8, 14.8; IR (Neat Film, NaCl) 3393, 3071, 
2974, 2935, 2876, 2839, 1730, 1682, 1430, 1359, 1341, 1275, 1240, 1220, 1176, 1158, 1138, 1113, 
1057, 1046, 1002, 930, 912, 879, 846, 816, 787, 745, 698 cm–1; HRMS (MM:ESI-APCI+) m/z 
calc’d for C17H26NO3 [M+H]+: 292.1907, found 292.1910. 
	
Tricyclic lactam 6 
A flame-dried 250 mL round bottom flask was charged with 14 (2.50 g, 8.58 mmol, 1.0 
equiv) and CH2Cl2 (86 mL). The resulting clear, colorless solution was cooled in a –78 ºC bath.  
After 15 min, LiEt3BH in (9.44 mL, 1.0 M in THF, 9.44 mmol, 1.1 equiv) was added dropwise 
over 5 min.  After 30 min, an additional portion of LiEt3BH (360 µL, 0.360 mmol, 0.042 equiv) 
was added.  After 10 min, an additional portion of LiEt3BH (300 µL, 0.300 mmol, 0.035 equiv) 
was added.  After stirring for 10 min, the reaction was complete by TLC analysis (40% EtOAc in 
hexanes).  EtOAc (210 µL, 2.15 mmol, 0.25 equiv) was added and the reaction was allowed to stir 
at –78 ºC.  After 1 h, BF3•OEt2 (2.11 mL, 17.2 mmol, 2.0 equiv) was added dropwise over 5 min.  
After 15 min, the reaction was complete by LC/MS analysis.  The reaction mixture was quenched 
with H2O (60 mL), warmed to 20 ºC, and transferred to a separatory funnel with CH2Cl2 (10 mL).  
OEt
N
O
O
14
LiEt3BH (1.2 equiv)
CH2Cl2, –78 ºC, 1 h;
EtOAc (0.25 equiv)
 –78 ºC, 1 h; N
O
O
6
then
BF3•OEt2 (2.0 equiv)
–78 ºC, 10 min
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The layers were separated and the aqueous was extracted with CH2Cl2 (3 x 25 mL).  The combined 
organics were dried over Na2SO4, filtered, and concentrated to afford a pale yellow oil.  
Purification by column chromatography (SiO2, 25% acetone in hexanes) yielded 6 as a white semi-
solid (1.8841 g, 7.62 mmol, 89% yield); [α]D25 –22.6 (c 1.0, CHCl3); 1H NMR (400 MHz, C6D6) δ 
5.91 (ddt, J = 17.4, 10.2, 7.5 Hz, 1H), 5.06–4.93 (m, 3H), 2.97 (dtd, J = 10.6, 5.5, 2.8 Hz, 1H), 
2.49 (dd, J = 13.7, 2.4 Hz, 1H), 2.29 (ddt, J = 17.1, 4.8, 2.6 Hz, 1H), 2.18 (dq, J = 7.4, 1.3 Hz, 
2H), 1.93 (dq, J = 4.9, 2.7 Hz, 1H), 1.91–1.72 (m, 4H), 1.48–1.30 (m, 2H), 1.25 – 1.15 (m, 1H), 
1.15–1.05 (m, 1H), 1.04 – 0.95 (m, 2H), 0.94–0.85 (m, 1H); 13C NMR (100 MHz, C6D6) δ 213.8, 
168.5, 134.1, 118.3, 59.9, 52.8, 51.6, 49.1, 39.6, 39.2, 33.3, 28.9, 26.7, 20.5, 19.7; IR (Neat Film, 
NaCl) 3074, 2937, 2870, 1716, 1644, 1460, 1440, 1416, 1346, 1264, 1235, 1166, 1120, 1064, 994, 
958, 916 cm–1; HRMS (MM:ESI-APCI+) m/z calc’d for C15H21NO2 [M+H]+: 248.1645, found 
248.1653. 
 
Amino alcohol 16  
A two-necked 250 mL round bottom flask equipped with a reflux condenser, septum, and 
stir bar was charged with 6 (905 mg, 3.66 mmol, 1.0 equiv) and THF (73 mL).  A flame-dried 25 
mL conical flask under N2 was charged with L-Selectride (5.90 mL, 1.0 M in THF, 5.90 mmol, 
1.6 equiv).  Both flasks were cooled to –78 ºC for 30 min, after which time the L-Selectride solution 
was slowly transferred to the flask containing 6 via syringe over 20 min via positive pressure 
cannulation, resulting in the formation of an opaque white reaction mixture.  After 30 min, the 
septum was exchanged for an oven-dried glass stopper and LiAlH4 (555.6 mg, 14.6 mmol, 4.0 
equiv) was added in a single portion to the reaction mixture. The reaction was then removed from 
the cooling bath and allowed to reach 20 ºC, after which time the flask was immersed in a 75 ºC 
oil bath.  After refluxing for 9 h, complete conversion to 16 was observed by LC/MS and TLC 
analysis. The reaction mixture was diluted with Et2O (50 mL) and cooled in an ice/water bath. 
After 10 min, the reaction was slowly quenched with dropwise addition of H2O (800 µL) over 10 
min, followed by the addition of aqueous NaOH (4.0 mL of a 2.5 M solution), and H2O2 (4.0 mL 
of a 30% solution).  The resulting gray suspension was then stirred vigorously for 30 min before 
being filtered through a pad of celite (5 x 5 cm), washing with EtOAc (3 x 75 mL). The filtrate 
L-Selectride (1.5 equiv)
THF, –78 ºC
then N
LiAlH4 (4.0 equiv)
–78 ºC to reflux
16
N
O
O
6
OH
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was then transferred to a separatory funnel and washed with H2O (60 mL) and brine (60 mL). The 
combined aqueous layers were extracted with EtOAc (3 x 80 mL). The combined organics were 
then dried over Na2SO4, filtered, and concentrated to a pale yellow oil. Purification by column 
chromatography (SiO2, 25% EtOAc in hexanes with 1% Et3N) afforded 16 as a colorless, viscous 
oil which slowly turns red with exposure to air (833.1 mg, 3.54 mmol, 97% yield); [α]D25 –13.4 (c 
1.0, CHCl3); 1H NMR (500 MHz, C6D6) δ 5.83 (dddd, J = 15.1, 11.2, 8.3, 7.6 Hz, 1H),	5.04 (app 
t, J = 1.2 Hz, 1H), 5.02–4.99 (m, 1H), 3.25 (m, 1H), 2.78–2.60 (m, 2H), 2.55 (d, J = 11.3 Hz, 1H), 
2.08–1.74 (m, 6H), 1.68–1.37 (m, 9H), 1.32–1.03 (m, 3H); 13C NMR (100 MHz, C6D6) δ 134.8, 
116.8, 75.4, 65.5, 65.4, 56.4, 43.3, 41.8, 37.8, 30.5, 30.0, 26.1, 24.7, 20.9, 20.0; IR (Neat Film, 
NaCl) 3404 (br), 3072, 2931, 2856, 2797, 2759, 1638, 1463, 1442, 1375, 1336, 1271, 1223, 1198, 
1182, 1124, 1106, 1044, 995, 958, 947, 912, 844, 813, 768, 714, 678, 635 cm–1; HRMS (MM:ESI-
APCI+) m/z calc’d for C15H26NO [M+H]+: 236.2009, found 236.2012.		
 
(–)-a,b-myrifabral A (4) 
In a nitrogen-filled glovebox, an oven-dried 25 mL round bottom flask was charged with 
amino alcohol 16 (100.0 mg, 0.424 mmol, 1.0 equiv), pinacol boronate 17 (356.2 mg, 2.12 mmol, 
5.0 equiv), and a Teflon-coated stir bar.  The flask was sealed with a septum, removed from the 
glovebox, and placed under an atmosphere of nitrogen. To the flask was added THF (2.2 mL) to 
provide a clear, colorless solution.  Hoveyda–Grubbs II catalyst (26.6 mg, 0.0424 mmol, 10 mol 
%) was then added rapidly in a single portion, and the flask was subjected to vacuum until the 
green solution began to bubble.  The dark green reaction was allowed to stir for 10 min under a 
static vacuum, at which point the flask was backfilled with nitrogen and an aliquot was analyzed 
by LC/MS, indicating full conversion of amino alcohol 16 to the putative cross metathesis product.  
Note: Typically, the reaction solution rapidly turns dark brown/black when the flask is backfilled 
with nitrogen.  The metathesis catalyst was quenched with the addition of ethyl vinyl ether (40 µL) 
at 20 °C.  After stirring for 30 min at 20 °C, deionized water (2.2 mL) and NaBO3•4H2O (1.30 g, 
8.48 mmol, 20.0 equiv) were added and the resulting black, biphasic suspension was stirred rapidly 
N
16
OH
(5.0 equiv)
HG II (10 mol %)
THF, 20 °C, 10 min
B
N
1.4:1 β:α-OH (–)-4
O OHthen
NaBO3•4H2O (20.0 equiv)
1:1 H2O/THF, 23 °C, 4 h
(17)
O
O
MeMe
Me
Me
Me
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at 20 °C.  After 4 h, full conversion of the intermediate cross metathesis product was observed by 
LC/MS analysis.  The reaction mixture was poured into a separatory funnel with EtOAc (5 mL) 
and H2O (10 mL). The layers were separated and the aqueous layer was extracted 3 x 5 mL EtOAc.  
The combined organics were dried over Na2SO4, filtered, and concentrated to yield a dark brown 
oil.  Purification by column chromatography (SiO2, 0®50% EtOAc in hexanes with 2% Et3N) 
yielded (–)-myrifabral A (4) as a 1.4:1 mixture of b:a-OH epimers as a viscous yellow oil (90.1 
mg, 0.358 mmol, 85% yield).  Note: racemic samples of this compound are isolated as a colorless 
solid, in accordance with previous reports.3,4 Due to the complicated overlap of b and a-OH 
epimers of (–)-4, the 1H NMR spectral data are reported with raw integration values; [α]D25 –41.4 
(c 1.0, CHCl3); 1H NMR (600 MHz, Pyridine-d5) δ 8.36 (s, 1.00), 7.70 (s, 0.72), 5.68 (d, J = 3.7 
Hz, 0.82), 5.10 (d, J = 9.6 Hz, 1.19), 4.19 (d, J = 3.4 Hz, 0.89), 3.21 (d, J = 3.6 Hz, 1.17), 2.80–
2.64 (m, 4.30), 2.54 (t, J = 10.7 Hz, 2.16), 2.30–2.19 (m, 2.22), 2.10 – 1.88 (m, 7.28), 1.88 – 1.80 
(m, 2.19), 1.78–1.72 (d, J = 11.9 Hz, 3.43), 1.68–1.59 (m, 8.86), 1.57–1.40 (m, 8.86), 1.27 – 1.05 
(m, 10.40); 13C NMR (100 MHz, Pyridine-d5) δ 98.3, 92.3, 80.7, 72.5, 69.6, 69.1, 66.8, 66.4, 57.2, 
57.2, 40.4, 40.2, 34.4, 33.1, 32.6, 30.7, 30.7, 30.6, 29.6, 29.6, 28.7, 27.5, 26.9, 26.9, 25.5, 25.5, 
21.4, 21.3, 21.3, 21.2; IR (Neat Film, NaCl) 3381 (br), 3054, 2933, 2851, 2796, 2756, 2728, 2253, 
1714, 1562, 1549, 1540, 1462, 1456, 1444, 1396, 1374, 1336, 1298, 1277, 1243, 1209, 1189, 1124, 
1106, 1077, 1057, 1009, 998, 961, 949, 928, 917, 902, 886, 870, 856, 840, 826, 762, 739, 704, 673 
cm–1, HRMS (MM:ESI-APCI+) m/z calc’d for C15H26NO2 [M+H]+: 252.1958, found 252.1960. 
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myrifabral A (4) comparison spectra
1H NMR, 600 MHz, Pyridine-d5
top: natural
bottom: synthetic
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(–)-a,b-myrifabral B (5) 
 The following procedure was adapted from Song’s total synthesis of (±)-myrifabral B.4 To 
a one dram vial with a stir bar was added (–)-4 (50.0 mg, 0.199 mmol, 1.0 equiv), THF (220 µL), 
2 N aqueous HCl (250 µL), and N-ethyl-N-(methoxymethyl)ethanamine (117.2 mg, 0.995 mmol, 
5.0 equiv) to provide a colorless, biphasic reaction mixture.  The vial was sealed with a Teflon-
lined cap and heated in a vial well at 80 °C with rapid stirring.  After 4 h, the reaction was complete 
by LC/MS analysis.  The vial was cooled to 20 °C, then the biphasic reaction mixture was poured 
into a separatory funnel with EtOAc (5 mL), and saturated aqueous NaHCO3 (10 mL). The layers 
were separated and the aqueous layer was extracted with EtOAc (3 x 5 mL).  The combined 
organics were dried over Na2SO4, filtered, and concentrated to a brown/yellow oil.  Purification 
by column chromatography (SiO2, 20®60% EtOAc in hexanes with 2% Et3N) yielded (–)-
myrifabral B (5) as a 1.6:1 mixture of b:a-OH epimers as a viscous yellow oil (29.5 mg, 0.0877 
myrifabral A (4) comparison spectra
13C NMR, 100 MHz, Pyridine-d5
top: natural
bottom: synthetic
N
1.6:1 α:β-OH (–)-5
O
OH
1.2:1 2 N HCl/THF
reflux, 4 h
N
(–)-4, 1.4:1 α:β-OH
O
OH
NEt2OMe (5.0 equiv)Et2N
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mmol, 44% yield).  Note: racemic samples of this compound are isolated as a colorless solid, in 
accordance with previous reports.3,4 Due to the complicated overlap of b and a-OH epimers of (–
)-5, the 1H NMR spectral data are reported with raw integration values; [α]D25 –37.5 (c 1.0, CHCl3); 
1H NMR (600 MHz, Pyridine-d5) δ 5.72 (d, J = 3.0 Hz, 1.00), 4.82 (d, J = 8.2 Hz, 1.67), 4.22 (d, 
J = 3.4 Hz, 1.01), 4.22 (d, J = 3.4 Hz, 1.40), 2.83–2.74 (m, 2.40), 2.73–2.68 (m, 3.86), 2.66 (dd, J 
= 12.7, 7.9 Hz, 1.75), 2.60 (dd, J = 10.9, 7.2 Hz, 2.92), 2.57–2.47 (m, 7.18), 2.45–2.33 (m, 6.41), 
2.28 (tdd, J = 13.1, 6.6, 2.4 Hz, 1.64), 2.21 (dd, J = 12.8, 6.1 Hz, 1.61), 2.15–2.01 (m, 4.23), 2.01–
1.93 (m, 4.26), 1.83–1.78 (m, 3.00), 1.73–1.60 (m, 9.07), 1.58–1.43 (m, 11.78), 1.39 (dd, J = 13.3, 
4.4 Hz, 1.56), 1.34–1.28 (m, 3.61 ), 1.25 (dt, J = 13.0, 3.1 Hz, 2.86), 1.21 – 1.09 (m, 3.00), 1.02 (t, 
J = 7.1 Hz, 5.89), 0.99 (t, J = 7.1 Hz, 8.22), 0.85 (t, J = 12.9 Hz, 1.39); 13C NMR (100 MHz, 
Pyridine-d5) δ 103.1, 94.2, 80.4, 72.6, 69.8, 69.0, 66.9, 66.4, 57.2, 57.2, 57.1, 56.8, 48.5, 48.0, 
40.1, 40.0, 39.1, 37.3, 35.2, 35.2, 33.8, 33.8, 30.7, 30.7, 30.5, 29.8, 26.9, 26.8, 25.5, 25.4, 21.6, 
21.4, 21.3, 21.3, 12.9, 12.4; IR (Neat Film, NaCl) 3076 (br), 2966, 2933, 2851, 2801, 2757, 2728, 
2251, 1722, 1692, 1557, 1462, 1444, 1375, 1346, 1297, 1276, 1267, 1243, 1205, 1196, 1178, 1144, 
1124, 1104, 1089, 1076, 1059, 1037, 967, 918, 904, 885, 813, 860, 833, 753, 715, 666, 616 cm–1, 
HRMS (FAB+) m/z calc’d for C20H37N2O2 [M+H]+: 337.2855, found 337.2857. 
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myrifabral B (5) comparison spectra
1H NMR, 600 MHz, Pyridine-d5
top: natural
bottom: synthetic
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	 13C	NMR	(100	MHz,	CDCl3)	of	compound	7.		
Infrared	spectrum	(Thin	Film,	NaCl)	of	compound	7.		
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	 	13C	NMR	(100	MHz,	C6D6)	of	compound	14.		
Infrared	spectrum	(Thin	Film,	NaCl)	of	compound	14.		
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	 	13C	NMR	(100	MHz,	CDCl3)	of	compound	6.		
Infrared	spectrum	(Thin	Film,	NaCl)	of	compound	6.		
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	 	13C	NMR	(100	MHz,	CDCl3)	of	compound	16.		
Infrared	spectrum	(Thin	Film,	NaCl)	of	compound	16.		
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																																																	 	 13C	NMR	(100	MHz,	pyridine-d5)	of	compound	(–)-4.		
Infrared	spectrum	(Thin	Film,	NaCl)	of	compound	(–)-4.		
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 13C	NMR	(100	MHz,	pyridine-d5)	of	compound	(–)-5.		
Infrared	spectrum	(Thin	Film,	NaCl)	of	compound	(–)-5.		
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